Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SKB565 injection in advanced solid tumors
CTR20262949Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB565 in Nonhematologic neoplasms, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
SKB565
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20262949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262949.